Azenta, Inc. ( (AZTA) ) has released its Q4 earnings. Here is a breakdown of the information Azenta, Inc. presented to its investors.
Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Azenta, Inc. is a global leader in life sciences solutions, specializing in cold-chain sample management and multiomics services for pharmaceutical, biotech, and healthcare institutions. The company recently released its fiscal year 2024 earnings report, highlighting a 4% revenue growth in its core segments and a strategic decision to sell its B Medical Systems unit to streamline its portfolio. Key financial metrics for the year included a 6% increase in Q4 revenue for Sample Management Solutions and an 8% rise in Multiomics revenue, despite an overall 1% decline in total revenue due to reduced B Medical Systems sales. Azenta also reported significant margin expansions and a strategic focus on cost reductions, culminating in a notable improvement in adjusted EBITDA margins. Moving forward, Azenta anticipates a 3% to 5% organic revenue growth in fiscal 2025, alongside further margin improvements, as it continues to focus on its core businesses and strategic initiatives.
